Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928480 | 0.84 | ALDH1A1 (0.63) | ALDH1A1KMT2ATDP1L3MBTL1ENPP2 | |
| SCHEMBL5391758 | 0.84 | ALDH1A1 (0.60) | ALDH1A1MAPTKMT2ATDP1L3MBTL1 | |
| SCHEMBL18425852 | 0.81 | ALDH1A1 (0.67) | HPGDALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL5402231 | 0.80 | ALDH1A1 (0.54) | ALDH1A1KMT2AMAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL4024622 | 0.80 | HTR2C (0.54) | — | |
| SCHEMBL5060936 | 0.79 | KDM4E (0.66) | ALDH1A1MAPTKMT2ALMNAMAPK1 | |
| SCHEMBL4028062 | 0.79 | ALDH1A1 (0.50) | ALDH1A1MAPTKMT2ATDP1L3MBTL1 | |
| SCHEMBL5378784 | 0.78 | ALDH1A1 (0.49) | HPGDALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL5388871 | 0.78 | ALDH1A1 (0.53) | HPGDALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL6921762 | 0.77 | PTGDR2 (0.63) | HPGDALDH1A1MAPTKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1497265-B1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2009-02-18 | — | — | EP | disclosed |
| US-20070191457-A1 | Compounds having activity at 5ht2c receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| US-20070191457-A1 | Compounds having activity at 5ht2c receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| US-20070191457-A1 | Compounds having activity at 5ht2c receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| EP-1603914-B1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2007-01-17 | — | — | EP | disclosed |
| EP-1603914-B1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2007-01-17 | — | — | EP | disclosed |
| EP-1611098-B1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LTD (GB) | 2006-12-27 | — | — | EP | disclosed |
| US-20060281786-A1 | Compounds having activity at 5ht2c receptor and uses thereof | GLAXO GROUP LIMITED (GB) | 2006-12-14 | — | — | US | disclosed |
| EP-1611098-A1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2006-01-04 | — | — | EP | disclosed |
| EP-1603914-A1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | GLAXO GROUP LIMITED | 2005-09-15 | — | — | US | disclosed |
| EP-1497265-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004089897-A1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004081010-A1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2004-09-23 | — | — | WO | disclosed |
| WO-2003089409-A1 | COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191457-A1 | Compounds having activity at 5ht2c receptor and uses thereof | HTR4, HTR7, HTR2C | HPGD 2064/4885ALDH1A1 2118/4885MAPT 4607/4885 |
| US-20050203079-A1 | Compounds having affinity at 5ht2C receptor and use thereof in therapy | HTR7, HTR2C, HTR3C | HPGD 1826/4885ALDH1A1 1439/4885MAPT 4698/4885 |
| US-20060281786-A1 | Compounds having activity at 5ht2c receptor and uses thereof | HTR2C, HTR4, HTR3C | HPGD 1179/4885ALDH1A1 1159/4885MAPT 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.